Literature DB >> 6617043

Steady-state pharmacokinetics of phenytoin from routinely collected patient data.

T H Grasela, L B Sheiner, B Rambeck, H E Boenigk, A Dunlop, P W Mullen, J Wadsworth, A Richens, T Ishizaki, K Chiba.   

Abstract

Previously reported routine phenytoin clinical pharmacokinetic data from Japan, England, and Germany were analysed to estimate population pharmacokinetic parameters. There were 780 steady-state phenytoin concentrations and associated dosage rates (mg/day) from 322 patients. The patient group spanned paediatric and adult ages, mean age being 18.4 +/- 17.3 (SD) years; 53% were males. The data were analysed using NONMEM, a computer programme designed for population pharmacokinetic analysis. Estimates of the influence of age, gender, data source, height and weight on the maximum elimination rate (Vm) and Michaelis-Menten constant (Km) were obtained. The Vm and Km of a 70 kg adult male European were estimated to be 415 mg/day and 5.7 mg/L, respectively. Vm is not influenced by gender, age or data source. The parameters of a power function of height and weight were estimated to adjust Vm for body size. The best function adjusts Vm in proportion to weight to the 0.6 power; height contains no useful information. Km is not influenced by gender. The Km for patients less than 15 years old is 43% less than that of older patients. The Km of Japanese patients appears to be 23% less than that for European patients. Even after adjustments for age, etc., apparent Vm and Km vary unpredictably among individuals with a coefficient of variation between 10 to 20% and approximately 50% respectively.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6617043     DOI: 10.2165/00003088-198308040-00006

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  19 in total

1.  DIPHENYLHYDANTOIN AND PHENOBARBITAL. SERUM LEVELS IN CHILDREN.

Authors:  O SVENSMARK; F BUCHTHAL
Journal:  Am J Dis Child       Date:  1964-07

2.  A formula to estimate the approximate surface area if height and weight be known. 1916.

Authors:  D Du Bois; E F Du Bois
Journal:  Nutrition       Date:  1989 Sep-Oct       Impact factor: 4.008

3.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.

Authors:  L B Sheiner; B Rosenberg; V V Marathe
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

4.  Energy metabolism, body size, and problems of scaling.

Authors:  K Schmidt-Nielsen
Journal:  Fed Proc       Date:  1970 Jul-Aug

5.  Predicting phenytoin dose - a revised nomogram.

Authors:  B Rambeck; H E Boenigk; A Dunlop; P W Mullen; J Wadsworth; A Richens
Journal:  Ther Drug Monit       Date:  1979       Impact factor: 3.681

Review 6.  Ethnic differences in drug metabolism.

Authors:  W Kalow
Journal:  Clin Pharmacokinet       Date:  1982 Sep-Oct       Impact factor: 6.447

7.  Predicting individual phenytoin dosage.

Authors:  S Vozeh; K T Muir; L B Sheiner; F Follath
Journal:  J Pharmacokinet Biopharm       Date:  1981-04

8.  The clinical pharmacokinetics of phenytoin.

Authors:  E Martin; T N Tozer; L B Sheiner; S Riegelman
Journal:  J Pharmacokinet Biopharm       Date:  1977-12

9.  Michaelis-Menten pharmacokinetics of diphenylhydantoin and application in the pediatric age patient.

Authors:  K Chiba; T Ishizaki; H Miura; K Minagawa
Journal:  J Pediatr       Date:  1980-03       Impact factor: 4.406

10.  Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1980-12
View more
  36 in total

1.  Pharmacokinetics of tolbutamide in ethnic Chinese.

Authors:  A S Gross; S Bridge; G M Shenfield
Journal:  Br J Clin Pharmacol       Date:  1999-02       Impact factor: 4.335

Review 2.  Therapeutic drug monitoring of phenytoin. Rationale and current status.

Authors:  M Levine; T Chang
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 3.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

Review 4.  Bayesian parameter estimation and population pharmacokinetics.

Authors:  A H Thomson; B Whiting
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

Review 5.  Population pharmacokinetic studies in pediatrics: issues in design and analysis.

Authors:  Bernd Meibohm; Stephanie Läer; John C Panetta; Jeffrey S Barrett
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

6.  Applying organ clearance concepts in a clinical setting.

Authors:  Jorge Duconge
Journal:  Am J Pharm Educ       Date:  2008-10-15       Impact factor: 2.047

7.  Evaluation of a bayesian pharmacokinetic program for phenytoin concentration predictions in outpatient population.

Authors:  J M Gaulier; R Boulieu; C Fischer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Apr-Jun       Impact factor: 2.441

8.  High-dose melphalan dosage adjustment: possibility of using a test-dose.

Authors:  B Tranchand; Y D Ploin; M P Minuit; C Sapet; P Biron; T Philip; C Ardiet
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 9.  Population pharmacokinetics. Theory and clinical application.

Authors:  B Whiting; A W Kelman; J Grevel
Journal:  Clin Pharmacokinet       Date:  1986 Sep-Oct       Impact factor: 6.447

10.  Phenytoin dosage predictions in paediatric patients.

Authors:  G J Yuen; P T Latimer; L C Littlefield; R W Mackey
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.